Nanobiotix (NBTX) Non-Current Assets (2018 - 2025)
Nanobiotix's (NBTX) quarterly Non-Current Assets came in at $5.8 million in Q4 2025, down 8.29% year-on-year from $6.4 million in Q4 2024, and down 2.5% quarter-over-quarter from $6.0 million in Q2 2025.
Nanobiotix (NBTX) Non-Current Assets (2018 - 2025) Analysis & Trends
Nanobiotix's Non-Current Assets history runs 8 years deep, the most recent figure standing at $5.8 million for Q4 2025.
- On a quarterly basis, Non-Current Assets fell 8.29% year-over-year to $5.8 million in Q4 2025; TTM through Dec 2025 was $5.8 million, a 8.29% decrease from a year earlier, with the FY2025 full-year figure at $5.7 million, down 10.99% from the prior year.
- Non-Current Assets declined to $5.8 million in Q4 2025 per NBTX's latest filing, from $6.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $10.0 million in Q4 2021 and bottomed at $5.8 million in Q4 2025.
- The 5-year median for Non-Current Assets is $7.2 million (2023), against an average of $7.5 million.
- Across the five-year window, Non-Current Assets fell 4.85% in 2021 and retreated 24.1% in 2022, its largest moves.
- Year by year, Non-Current Assets stood at $10.0 million in 2021, then slipped by 24.1% to $7.6 million in 2022, then decreased by 6.69% to $7.1 million in 2023, then fell by 9.88% to $6.4 million in 2024, then decreased by 8.29% to $5.8 million in 2025.
- Per Business Quant, the three latest NBTX Non-Current Assets figures stand at $5.8 million (Q4 2025), $6.0 million (Q2 2025), and $6.4 million (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 5.83 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.95 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 285.82 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 910.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.83 Mn |
| Jun 30, 2025 | 5.98 Mn |
| Dec 31, 2024 | 6.36 Mn |
| Jun 30, 2024 | 6.70 Mn |
| Dec 31, 2023 | 7.06 Mn |
| Jun 30, 2023 | 7.38 Mn |
| Dec 31, 2022 | 7.56 Mn |
| Jun 30, 2022 | 8.29 Mn |
| Dec 31, 2021 | 9.96 Mn |
| Jun 30, 2021 | 9.69 Mn |
| Dec 31, 2020 | 10.47 Mn |
| Dec 31, 2019 | 11.16 Mn |
| Dec 31, 2018 | 4.05 Mn |